WILLIAM R. VOGLER, M.D.; SIDNEY OLANSKY, M.D., F.A.C.P.
A double-blind study of the effect of 6-azauridine triacetate (azaribine) in psoriasis was conducted. One group received azaribine in a dose of 200 mg/kg of body weight per day for 6 weeks. The second group received placebo. Patients who failed to improve or relapsed were switched to the other group (studies A and B). Responses were judged as follows: excellent (complete clearing of lesions), good (75% reduction in size and thickness of lesions), fair (50% reduction in size and thickness of lesions), no improvement, and worse. After the double-blind study 11 patients were treated with azaribine in a dose of 100 mg/kg of body weight per day for 12 weeks (study C). Nine were then treated with optimal dose (study D). Twenty-two patients completed studies A and B. The responses to azaribine were 5, excellent; 11, good; 2, fair; 1, no improvement; and 3, worse. The responses to placebo were 0, excellent; 2, good; 2, fair; 1 no improvement; and 17, worse. The responses in study C were 1, excellent; 7, good; and 3, fair; and in study D there were 7 good and 2 fair. Mild marrow depression was the only toxicity observed.
WILLIAM R. VOGLER, SIDNEY OLANSKY. A Double-Blind Study of Azaribine in the Treatment of Psoriasis. Ann Intern Med. 1970;73:951–956. doi: 10.7326/0003-4819-73-6-951
Download citation file:
Published: Ann Intern Med. 1970;73(6):951-956.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use